Committee Action
On February 1, 2023, the Subcommittee on Health held a
hearing on H.R. 501. The Subcommittee received testimony from:
Mr. Kemp Chester, Senior Advisor,
International Relations and Supply Reduction, Office of
National Drug Control Policy (ONDCP)
Dr. Neeraj Gandotra, Chief Medical Officer,
Substance Abuse and Mental Health Services
Administration (SAMHSA)
Mr. Jon C. DeLena, Associate Administrator,
Business Operations, Drug Enforcement Administration
(DEA)
Ms. Kandi Pickard, President and CEO,
National Down Syndrome Society (NDSS)
Mr. Frederick Isasi, J.D. MPH, Executive
Director, Families USA
Ms. Molly Cain, Parent Advocate
Dr. Stephen Loyd, MD, Chief Medical Officer,
Cedar Recovery
Dr. Timothy Westlake, MD, Emergency Medicine
Physician
On March 8, 2023, the Subcommittee on Health met in open
markup session and forwarded H.R. 501, without amendment, to
the full Committee by a record vote of 28 yeas and 0 nays. On
March 24, 2023, the full Committee on Energy and Commerce met
in open markup session and ordered H.R. 501, as amended,
favorably reported to the House by a record vote of 44 yeas and
0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to require
DEA registrants to report and stop suspicious orders of control
substances. This will ensure that DEA registrants will better
coordinate with DEA and properly track and block suspicious
orders.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 501 is known to be duplicative of another Federal program,
including any program that was included in a report to Congress
pursuant to section 21 of Public Law 111-139 or the most recent
Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 501:
On February 1, 2023, the Subcommittee on Health held a
hearing on H.R. 501. The Subcommittee received testimony from:
Mr. Kemp Chester, Senior Advisor,
International Relations and Supply Reduction, Office of
National Drug Control Policy (ONDCP)
Dr. Neeraj Gandotra, Chief Medical Officer,
Substance Abuse and Mental Health Services
Administration (SAMHSA)
Mr. Jon C. DeLena, Associate Administrator,
Business Operations, Drug Enforcement Administration
(DEA)
Ms. Kandi Pickard, President and CEO,
National Down Syndrome Society (NDSS)
Mr. Frederick Isasi, J.D. MPH, Executive
Director, Families USA
Ms. Molly Cain, Parent Advocate
Dr. Stephen Loyd, MD, Chief Medical Officer,
Cedar Recovery
Dr. Timothy Westlake, MD, Emergency Medicine
Physician
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 501 contains no earmarks, limited tax
benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of ``Block, Report, and
Suspend Suspicious Shipments Act.''
Section. 2. Block, report, and suspend suspicious orders
Section 2 amends section 312(a) of the Controlled
Substances Act to require DEA registrants to either (1) decline
to fill suspicious orders or (2) conduct due diligence and
either fill the order or decline to fill the order depending on
if the registrant was able to dispel all suspicious indicators.
This section also requires DEA to promulgate a final rule
specifying the indicators that give rise to a suspicion that,
if an order or series of orders is filled, the drugs that are
the subject of the order or series of orders are likely to be
diverted and instances in which registrants do not have to
report suspicious orders to DEA. This section clarifies that
the penalties described in 312(a)(3) apply.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
CONTROLLED SUBSTANCES ACT
* * * * * * *
TITLE II--CONTROL AND ENFORCEMENT
* * * * * * *
Part C--Registration of Manufacturers, Distributors, and Dispensers of
Controlled Substances; Piperidine Reporting
* * * * * * *
SEC. 312. SUSPICIOUS ORDERS.
(a) Reporting.--Each registrant shall--
(1) design and operate a system to identify
suspicious orders for the registrant;
(2) ensure that the system designed and operated
under paragraph (1) by the registrant complies with
applicable Federal and State privacy laws; [and]
[(3) upon discovering a suspicious order or series of
orders, notify the Administrator of the Drug
Enforcement Administration and the Special Agent in
Charge of the Division Office of the Drug Enforcement
Administration for the area in which the registrant is
located or conducts business.]
(3) determine whether an order or series of orders is
suspicious, taking into consideration--
(A) any unusual size, pattern, or frequency
of the order or series of orders; and
(B) any customer business model, dispensing
patterns, prior orders, or other
characteristics that may indicate the order or
series of orders is suspicious, despite the
particular order or series of orders not
exhibiting an unusual size, pattern, or
frequency; and
(4) upon discovering suspicious circumstances
regarding an order or series of orders, and in a manner
consistent with the other requirements of this
section--
(A) decline to fill the order or series of
orders, establish and maintain (for not less
than a period to be determined by the
Administrator of the Drug Enforcement
Administration) a record of the order or series
of orders, and notify the Administrator of the
Drug Enforcement Administration for the purpose
of including information on such order or
series of orders in the centralized database
established under subsection (b)(1); or
(B) exercise due diligence as appropriate
and--
(i)(I) if the due diligence fails to
dispel all of the indicators that give
rise to the suspicion that, if the
order or series of orders is filled,
the drugs that are the subject of the
order or series of orders are likely to
be diverted, decline to fill the order
or series of orders; or
(II) if the due diligence does dispel
all such indicators, fill the order or
series of orders;
(ii) establish and maintain (for not
less than a period to be determined by
the Administrator of the Drug
Enforcement Administration) a record of
the order or series of orders and the
due diligence that was performed; and
(iii) notify the Administrator of the
Drug Enforcement Administration for the
purpose of including information on
such order or series of orders in the
centralized database established under
subsection (b)(1), including any
indicators giving rise to the suspicion
that, if the order or series of orders
is filled, the drugs that are the
subject of the order or series of
orders are likely to be diverted.
(b) Suspicious Order Database.--
(1) In general.--Not later than 1 year after the date
of enactment of this section, the Attorney General
shall establish a centralized database for collecting
reports of suspicious orders.
(2) Satisfaction of reporting requirements.--If a
registrant reports a suspicious order to the
centralized database established under paragraph (1),
the registrant shall be considered to have complied
with the requirement under subsection (a)(3) to notify
the Administrator of the Drug Enforcement
Administration and the Special Agent in Charge of the
Division Office of the Drug Enforcement Administration
for the area in which the registrant is located or
conducts business.
(c) Sharing Information With the States.--
(1) In general.--The Attorney General shall prepare
and make available information regarding suspicious
orders in a State, including information in the
database established under subsection (b)(1), to the
point of contact for purposes of administrative, civil,
and criminal oversight relating to the diversion of
controlled substances for the State, as designated by
the Governor or chief executive officer of the State.
(2) Timing.--The Attorney General shall provide
information in accordance with paragraph (1) within a
reasonable period of time after obtaining the
information.
(3) Coordination.--In establishing the process for
the provision of information under this subsection, the
Attorney General shall coordinate with States to ensure
that the Attorney General has access to information, as
permitted under State law, possessed by the States
relating to prescriptions for controlled substances
that will assist in enforcing Federal law.
Part D--Offenses and Penalties
* * * * * * *
prohibited acts b--penalties
Sec. 402. (a) It shall be unlawful for any person--
(1) who is subject to the requirements of part C to
distribute or dispense a controlled substance in
violation of section 309;
(2) who is a registrant to distribute or dispense a
controlled substance not authorized by his registration
to another registrant or other authorized person or to
manufacture a controlled substance not authorized by
his registration;
(3) who is a registrant to distribute a controlled
substance in violation of section 305 of this title;
(4) to remove, alter, or obliterate a symbol or label
required by section 305 of this title;
(5) to refuse or negligently fail to make, keep, or
furnish any record, report, notification, declaration,
order or order form, statement, invoice, or information
required under this title or title III, including any
such violation of section 312(a)(4);
(6) to refuse any entry into any premises or
inspection authorized by this title or title III;
(7) to remove, break, injure, or deface a seal placed
upon controlled substances pursuant to section 304(f)
or 511 or to remove or dispose of substances so placed
under seal;
(8) to use, to his own advantage, or to reveal, other
than to duly authorized officers or employees of the
United States, or to the courts when relevant in any
judicial proceeding under this title or title III, any
information acquired in the course of an inspection
authorized by this title concerning any method or
process which as a trade secret is entitled to
protection, or to use to his own advantage or reveal
(other than as authorized by section 310) any
information that is confidential under such section;
(9) who is a regulated person to engage in a
regulated transaction without obtaining the
identification required by 310(a)(3);
(10) negligently to fail to keep a record or make a
report under section 310 or negligently to fail to
self-certify as required under section 310;
(11) to distribute a laboratory supply to a person
who uses, or attempts to use, that laboratory supply to
manufacture a controlled substance or a listed
chemical, in violation of this title or title III, with
reckless disregard for the illegal uses to which such a
laboratory supply will be put;
(12) who is a regulated seller, or a distributor
required to submit reports under subsection (b)(3) of
section 310--
(A) to sell at retail a scheduled listed
chemical product in violation of paragraph (1)
of subsection (d) of such section, knowing at
the time of the transaction involved
(independent of consulting the logbook under
subsection (e)(1)(A)(iii) of such section) that
the transaction is a violation; or
(B) to knowingly or recklessly sell at retail
such a product in violation of paragraph (2) of
such subsection (d);
(13) who is a regulated seller to knowingly or
recklessly sell at retail a scheduled listed chemical
product in violation of subsection (e) of such section;
(14) who is a regulated seller or an employee or
agent of such seller to disclose, in violation of
regulations under subparagraph (C) of section
310(e)(1), information in logbooks under subparagraph
(A)(iii) of such section, or to refuse to provide such
a logbook to Federal, State, or local law enforcement
authorities;
(15) to distribute a scheduled listed chemical
product to a regulated seller, or to a regulated person
referred to in section 310(b)(3)(B), unless such
regulated seller or regulated person is, at the time of
such distribution, currently registered with the Drug
Enforcement Administration, or on the list of persons
referred to under section 310(e)(1)(B)(v);
(16) to violate subsection (e) of section 825 of this
title; or
(17) in the case of a registered manufacturer or
distributor of opioids, to fail to review the most
recent information, directly related to the customers
of the manufacturer or distributor, made available by
the Attorney General in accordance with section 307(f).
As used in paragraph (11), the term ``laboratory supply'' means
a listed chemical or any chemical, substance, or item on a
special surveillance list published by the Attorney General,
which contains chemicals, products, materials, or equipment
used in the manufacture of controlled substances and listed
chemicals. For purposes of paragraph (11), there is a
rebuttable presumption of reckless disregard at trial if the
Attorney General notifies a firm in writing that a laboratory
supply sold by the firm, or any other person or firm, has been
used by a customer of the notified firm, or distributed further
by that customer, for the unlawful production of controlled
substances or listed chemicals a firm distributes and 2 weeks
or more after the notification the notified firm distributes a
laboratory supply to the customer. For purposes of paragraph
(15), if the distributor is temporarily unable to access the
list of persons referred to under section 310(e)(1)(B)(v), the
distributor may rely on a written, faxed, or electronic copy of
a certificate of self-certification submitted by the regulated
seller or regulated person, provided the distributor confirms
within 7 business days of the distribution that such regulated
seller or regulated person is on the list referred to under
section 310(e)(1)(B)(v).
(b) It shall be unlawful for any person who is a registrant
to manufacture a controlled substance in schedule I or II, or
ephedrine, pseudoephedrine, or phenylpropanolamine or any of
the salts, optical isomers, or salts of optical isomers of such
chemical, which is--
(1) not expressly authorized by his registration and
by a quota assigned to him pursuant to section 306; or
(2) in excess of a quota assigned to him pursuant to
section 306.
(c)(1)(A) Except as provided in subparagraph (B), (C), or (D)
of this paragraph and paragraph (2), any person who violates
this section shall, with respect to any such violation, be
subject to a civil penalty of not more than $25,000. The
district courts of the United States (or, where there is no
such court in the case of any territory or possession of the
United States, then the court in such territory or possession
having the jurisdiction of a district court of the United
States in cases arising under the Constitution and laws of the
United States) shall have jurisdiction in accordance with
section 1355 of title 28 of the United States Code to enforce
this paragraph.
(B)(i) Except as provided in clause (ii), in the case of a
violation of paragraph (5), (10), or (17) of subsection (a),
the civil penalty shall not exceed $10,000.
(ii) In the case of a violation described in clause (i)
committed by a registered manufacturer or distributor of
opioids and related to the reporting of suspicious orders for
opioids, failing to maintain effective controls against
diversion of opioids, or failing to review the most recent
information made available by the Attorney General in
accordance with section 307(f), the penalty shall not exceed
$100,000.
(C) In the case of a violation of paragraph (16) of
subsection (a) of this section by an importer, exporter,
manufacturer, or distributor (other than as provided in
subparagraph (D)), up to $500,000 per violation. For purposes
of this subparagraph, a violation is defined as each instance
of importation, exportation, manufacturing, distribution, or
possession with intent to manufacture or distribute, in
violation of paragraph (16) of subsection (a).
(D) In the case of a distribution, dispensing, or possession
with intent to distribute or dispense in violation of paragraph
(16) of subsection (a) of this section at the retail level, up
to $1000 per violation. For purposes of this paragraph, the
term ``at the retail level'' refers to products sold, or held
for sale, directly to the consumer for personal use. Each
package, container or other separate unit containing an
anabolic stero